Abstract
The present disclosure relates to a mutant neuroserpin protein or portion thereof, to a nucleic acid comprising nucleotide sequence which encodes a mutant neuroserpin protein or portion thereof, and to use of the nucleic acid or mutant neuroserpin protein or portion thereof for treating glaucoma and other disorders associated with elevated plasmin activity.
Original language | English |
---|---|
Patent number | WO2022133521 |
IPC | C12N 15/ 86 A I,C07K 14/81 |
Priority date | 15/07/21 |
Publication status | Published - 30 Jun 2022 |